RxDoctor Payments Data

Anthony Schore, MD

Gastroenterology · Prospect, CTNPI 1861538431

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 866 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 46 manufacturers reported payments, led by AbbVie at 26.5% of the total.

$16,960in general payments, 2019–2025

Across 866 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Gilead$1K
  • Johnson & Johnson$1K
  • Bristol Myers Squibb$936
  • Pfizer$931
  • plus $6K from 40 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$16,893100%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,960 in reported general payments places this provider in the 85th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$116,996
Medicare patients
362
Services billed
1,647

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide52$49,650
VoqueznaVonoprazan Fumarate13$22,375
Mesalamine30$16,507
Dexlansoprazole DrDexlansoprazole34$11,438
Omeprazole235$3,196
Dicyclomine Hcl114$2,979
Sucralfate19$2,169
Mercaptopurine18$2,058
Pantoprazole Sodium160$1,678
Esomeprazole Magnesium46$1,086
Famotidine52$620
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$350
Lansoprazole18$288
Ciprofloxacin Hcl17$124
Metronidazole14$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$4,486$49,65052 claims
Phathom Pharmaceuticals, Inc.Voquezna$348$22,37513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Prospect

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →